抗生素89－07联合氟氧头孢实验治疗mec　A基因阳性MRSA感染小鼠败血症体内抗菌疗效  

In vivo activity of antibiotic 89-07 combined with flomoxef in the experimental therapy of mouse septicemia infected by mec A gene positive MRSA

作　　者：李家泰[1] 陈琼[1] 许军[1] 

机构地区：[1]北京医科大学临床药理研究所

出　　处：《中国抗生素杂志》1995年第6期425-427,共3页Chinese Journal of Antibiotics

基　　金：李家泰教授卫生部科学基金

摘　　要：应用ｍｅｃＡ基因阳性的甲氧西林耐药金葡球菌２株临床分离菌株，金葡球菌９２－１０６与８９－１８７感染小鼠引起的小鼠败血症实验模型，评价抗生素８９－０７与氟氧头孢联合方案的体内抗菌活性并与去甲万古霉素单独给药进行比较。结果表明去甲万古霉素治疗金葡球菌９２－１０６和８９－１８７引起的小鼠ＭＲＳＡ感染的半数有效剂量ＥＤ５０值分别为５．８±１．１和４．１±０．８ｍｇ／ｋｇ，均显著低于抗生素８９－０７（１０．０，１０．５ｍｇ／ｋｇ）或氟氧头孢（２６；９，２９．２ｍｇ／ｋｇ）。抗生素８９－０７与氟氧头孢联合治疗ＭＲＳＡ９２－１０６与８９－１８７感染小鼠的ＥＤ５０值分别为３．８与２．５ｍｇ／ｋｇ。均显著低于去甲万古霉素、抗生素８９－０７和氟氧头孢相应的ＥＤ５０值。说明抗生素８９－０７与氟氧头孢联合方案的体内抗菌活性比去甲万古霉素强，具有统计学显著意义（Ｐ＜０．０１）。表明两药联合具有很好的体内协同作用。An experimental model of motise septicemia infected by two strains of mecAgene positive MRSA,S. aureus 92-106 and 89-187, isolated from clinic, was used forevaltiating in vivo activity of antibiotic 89-07 and flomoxef combination regimen comparedwith norvancomvcin, a demethyl derivative of vancomycin. Antibiotic 89-07 is a newaminoglycoside developed in China and flomoxef is a new oxacephem provided by ShionogiCompany。 Results showed that the ED50s of norvancomycin in the treatment of mice MRSAinfections infected by S。 aureus 92-106 and 89-197 were 5.8±1. 1 and 4.1±0.8mg/kgrespectively, both were significantly lower than that of antibiotic 89-07 or flomoxef usedalone。 The ED50s of the combination of antibiotic 89-07 and flomoxef in the treatment ofMRSA 92-106 and 89-187 infections were 3. 8 and 2; 5mg/kg respectively,both were sig-nificantly lower than those of norvancomycin(5.8,4. lmg/kg),antlbiotic89-07(10.0, 10. 5mg/kg), and flomoxef(26.9,29.2mg/kg).Our resultsindicated that the in vivo antibacterial activitv of the antibiotic 89- 07 and flomoxefcombination regimen was stronger than that of norvancomycin with statistically significantdifference(P<0. 01),and the results also showed a good in vivo synergism of antibiotic 89-07combined with flomoxef.

关 键 词：抗生素 89-07 氟氧头孢 败血症 甲氧西林 球菌 

分 类 号：R515.305[医药卫生—内科学] R978.12[医药卫生—临床医学]